Homocysteine and Essential Hypertension

Journal of Clinical Pharmacology

Volumn 43, Issue 12, 2003, Pages 1299-1306

  Rodrigo, Ramón ^a   Passalacqua, Walter ^a   Araya, Julia ^a   Orellana, Myriam ^a   Rivera, Gonzalo ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Endothelial dysfunction; Folic acid; Free radicals; Homocysteine; Hypertension; Vitamin B

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; FOLIC ACID; HOMOCYSTEINE; NITRATE; NITRIC OXIDE; PYRIDOXINE;

BIOAVAILABILITY; BLOOD LEVEL; BLOOD PRESSURE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; ESSENTIAL HYPERTENSION; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; RANDOMIZATION; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANTIOXIDANTS; ENDOTHELIUM, VASCULAR; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; VITAMIN B 12;

EID: 0242721768     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258190     Document Type: Review

References (88)

1. Waeber B, Brunner HR: The multifactorial nature of hypertension: the greatest challenge for its treatment? J Hypertens 2001; 19(Suppl.):S9-S16.
2. Plante GE: Vascular response to stress in health and disease. Metabolism 2002;51(6, Pt. 2):25-30.
3. Pryor WA, Squadrito GI: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:L699-L722.
4. Dohi Y, Thiel MA, Buhler FR, Lüscher TF: Activation of endothelial L-arginine pathway in resistance arteries: effect of age and hypertension. Hypertension 1990;16:170-179.
5. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-1474.
6. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002;346:1954-1962.
7. Virdis A, Ghiadoni L, Salvetti G, Versari D, Taddei S, Salvett A: Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension? J Nephrol 2002;15:414-421.
8. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS: Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000;279:F671-F678.
9. Voutilainen S, Morrow JD, Roberts LJ, Alfthan G, Alho H, Nyyssönen K, et al: Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vase Biol 1999;19:1263-1266.
10. van Guldener C, Stehouwer CD: Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000;26:281-289.
11. Wilcox CS: Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 2002;4:160-166.
12. Makino A, Skelton MM, Zou AP, Roman RJ, Cowley AW Jr: Increased renal medullary oxidative stress produces hypertension. Hypertension 2002;39(2, Pt. 2):667-672.
13. Parik T, Allikmets K, Teesalu R, Zilmer M: Evidence for oxidative stress in essential hypertension: perspective for antioxidant therapy. J Cardiovasc Risk 1996;3:49-54.
14. Romero JC, Reckelhoff JF: Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999;34(Pt. 2):943-949.
15. Negishi H, Njelekela M, Ikeda K, Sagara M, Noguchi T, Kuga S, et al: Assessment of in vivo oxidative stress in hypertensive rats and hypertensive subjects in Tanzania, Africa. Hypertens Res 2000; 23:285-289.
16. Dhalla NS, Temsah RM, Netticadan T: Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.
17. Maxwell SR: Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 2000;95(Suppl. 1):165-171.
18. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C: High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-1749.
19. Mendis S, Athauda SB, Naser M, Takahashi K: Association between hyperhomocysteinaemia and hypertension in Sri Lankans. J Int Med Res 1999;27:38-44.
20. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG: A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001;14:627-631.
21. Boers GHJ: Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291-295.
22. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2001;61:609-614.
23. Li N, Chen YF, Zou AP: Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002;39(2, Pt. 2):443-448.
24. Finkelstein JD: Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-225.
25. Krajcovicova-Kudlackova M, Blazicek P, Kopcova J, Bederova A, Babinska K: Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 2000;44:135-138.
26. Hung CJ, Huang PC, Lu SC, Li YH, Huang HB, Lin BF, et al: Plasma homocysteine levels in Taiwanese vegetarians are higher than those of omnivores. J Nutr 2002;132:152-158.
27. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ: Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
28. Genest J: Hyperhomocyst(e)inemia-determining factors and treatment. Can J Cardiol 1999;15(Suppl. B):35B-38B.
29. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau M, et al: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
30. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-10103.
31. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW: Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001;276:46896-46904.
32. Kanani PM. Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG: Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999;100:1161-1168.
33. Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, et al: Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001;38:1106-1115.
34. Schnackenberg CG: Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2002;2:121-125.
35. Schnackenberg CG: Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002;282:R335-R342.
36. Morrow JD, Hill KE, Burk KF, Nammour TM, Badr KF, Roberts LJ II: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-9387.
37. Takahashi K, Nammour TK, Fukunaga M, Ebert J, Morrow JD, Roberts LJI, et al: Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat: evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992;90: 136-141.
38. Fukunaga M, Makita N, Roberts LJI, Morrow JD, Takahashi K, Badr KF: Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993;264:C1619-C1624.
39. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A: Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 1999;56:471-478.
40. Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA: Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002;105:452-456.
41. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation: contribution to alteration of vasomotor tone. J Clin Invest 1996;97:1916-1923.
42. Laragh JH: The meaning of plasma renin measurements: renin and sodium volume-mediated (low renin) forms of vasoconstriction in experimental and human hypertension and in the oedematous states of nephrosis and heart failure. J Hypertens 1984;1:141-150.
43. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA: Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 2000;14:271-278.
44. Ortiz MC, Manriquez MC, Romero JC, Juncos LA: Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 2001;38(3, Pt. 2):655-659.
45. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Harber E, Schlegel R, et al: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
46. Miller A, Mujumdar V, Shek E, Guillot J, Angelo M, Palmer L, et al: Hyperhomocyst(e)inemia induces multiorgan damage. Heart Vessels 2000;15:135-143.
47. Raziel A, Kornberg Y, Friedler S, Schachter M, Sela BA, Ron-El R: Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol 2001;45:65-71.
48. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-1376.
49. Kottke-Marchant K, Green R, Jacobsen D, Discorteto P: Subcytotoxic homocysteine increases monocyte adhesion to human aortic endothelial cells. Blood 1990;76:511-517.
50. Tyagi SC: Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol Cell Physiol 1998;274:C396-C405.
51. Wang G, Siow YL: Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000;15(352, Pt. 3):817-826.
52. Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Hueck-Steadt TP, Ghio AJ, et al: Reactive oxygen species from NADPH:quinone oxidoreductase constitutively activate NF-κB in malignant melanoma cells. Am J Physiol Cell Physiol 2001;280:C659-C676.
53. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, et al: Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999;94:959-967.
54. Collins T, Cybulsky MI: NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-264.
55. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Moll Cell Biol 1999;19:5785-5799.
56. Mujumdar VS, Chandra M, Tummalapalli CM, Aru GM, Tyagi SC: Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am J Physiol Cell Physiol 2002;282:C1009-C1015.
57. Mujumdar VS, Aru GM, Tyagi SC: Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biol 2001;82:491-500.
58. Jackson SH: The reaction of homocysteine with aldehyde: an explanation of the collagen defects in homocystinuria. Clin Chim Acta 1973;45:215-217.
59. Majors A, Ehrhart LA, Pezacka EH: Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-2081.
60. Lim PO, Tzemos N, Farquharson CA, Anderson JE, Deegan P, MacWalter RS, et al: Reversible hypertension following celiac disease treatment: the role of moderate hyperhomocysteinaemia and vascular endothelial dysfunction. J Hum Hypertens 2002;16:411-415.
61. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, et al: Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272:17012-17017.
62. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, et al: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11.
63. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-23841.
64. Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, et al: Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 1999;29:100-108.
65. Rashuveer G, Sinkey CA, Chenard C, Stumbo P, Haynes WG: Effect of vitamin E on resistance vessel endothelial dysfunction induced by methionine. Am J Cardiol 2001;88:285-290.
66. Okatani Y, Wakatsuki A, Reiter RJ: Protective effect of melatonin against homocysteine-induced vasoconstriction of human umbilical artery. Biochem Biophys Res Commun 2000;277:470-475.
67. Jacobsen DW: Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833-1843.
68. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
69. Refsum H, Ueland P, Nygard O, Vollset SE: Homocysteine and cardiovascular diseases. Annu Rev Med 1998;49:31-62.
70. Clarke R, Smith AD, Jobst KA, Vollset SE, Refsum H, Sutton L, et al: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
71. Miller JW: Homocysteine, Alzheimer's disease, and cognitive function. Nutrition 2000;16:675-677.
72. Bostom AG, Lathorp L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology and potential association to atherosclerotic outcomes. Kidney Int 1997;52:10-20.
73. Virdis A, Ghiadoni L, Salvetti G, Versari D, Taddei S, Salvett A: Hyperhomocyst(e)inemia: is a novel risk factor in hypertension? J Nephrol 2002;15:414-421.
74. Tsioufis C, Antoniadis D, Stefanadis C, Tzioumis K, Pitsavos C, Kallikazaros I, et al: Relationships between new risk factors and circadian blood pressure variation in untreated subjects with essential hypertension. Am J Hypertens 2002;15:600-604.
75. Prasad K: Homocysteine, a risk factor for cardiovascular disease. Int J Angiol 1999;8:76-86.
76. den Heijer M, Brouwer IA, Bos GMJ, Blom HJ, van der Put NM, Spaans AP, et al: Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-361.
77. Haynes WG: Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002:16:391-399.
78. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC: Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther 2002;303:158-162.
79. Digiesi V, Lenuzza M, Digiesi G: Prospects for the use of antioxidant therapy in hypertension. Ann Ital Med Int 2001;16:93-100.
80. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-1124.
81. John JH, Ziebland S, Yudkin P, Roe LS, Neil HAW: Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Lancet 2002;359:1969-1974.
82. Block G: Ascorbic acid, blood pressure, and the American diet. Ann NY Acad Sci 2002;959:180-187.
83. Duffy SJ, Gokce N, Holbrook M. Hunter LM, Biegelsen ES, Huang A, et al: Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 2001;280:H528-H534.
84. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V: Dietary vitamin C supplementation lowers blood pressure in spontaneously hypertensive rats. Moll Cell Biochem 2001;218:97-103.
85. On YK, Kim CH, Sohn DW, Oh BH, Lee MM, Park YB, et al: Improvement of endothelial function and vitamin C in essential hypertension. Korean J Intern Med 2002;17:131-137.
86. Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, et al: Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:377-386.
87. Westphal S, Rading A, Luley C, Dierkes J: Antihypertensive treatment and homocysteine concentrations. Metabolism 2003;52:261-263.
88. Sharabi Y, Doolman R, Rosenthal T, Grossman E, Rachima-Maoz C, Nussinovitch N, et al: Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens 1999;12(8, Pt. 1):766-771.